NCT02957786
11 evidence topics · 1 source
Objective
Comparative objective
Location and study date
Study design
Allocation and masking
Eligibility criteria
Treatment
Treatment duration
| Characteristic | Quoted value |
|---|---|
| Cytisine and varenicline courses | “12 weeks” |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome timing
| Characteristic | Quoted value |
|---|---|
| Verified continuous-abstinence assessment | “6 months” |
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Missing-data analysis
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Enrollment was 679 participants compared with a planned 2,140. The open-label design and recruitment below target limit precision and leave potential reporting and performance bias. The population and 12-week cytisine regimen differ from other historical cytisine trials.